Last checked at 30 Apr 2019 07:00
(AIM: SAR) 30 April 2019
Sareum Holdings PLC
("Sareum" or the "Company")
Sareum to Present at BioTrinity 2019 in London
Sareum Holdings plc (AIM:SAR), the specialist small molecule drug development business, announces that its CEO, Dr Tim Mitchell, will give a company presentation at BioTrinity 2019 in London, which takes place from 30 April - 1 May.
The presentation, to be held today at 11:05am BST, will introduce Sareum and provide an overview of its lead programmes, including SRA737, a novel Chk1 inhibitor licensed to Sierra Oncology (NASDAQ: SRRA) and its two TYK2/JAK1 kinase programmes, SDC-1801 and SDC-1802, targeting autoimmune diseases and cancers.
Presentation details are as follows:
Date: Tuesday 30 April 2019
Time: 11.05am BST
Session: BioLaunchPad Showcase Session One
A copy of the presentation will be made available on the company website after the event in the News section.
BioTrinity is Europe's leading Biopartnering and Investment conference, and generates unrivalled opportunities for life science companies, academics, investors, and major pharmaceutical players to come together to do deals and establish collaborations.
For further information, please contact:
Sareum Holdings plc |
|
Tim Mitchell | 01223 497 700 |
WH Ireland Limited (Nominated Adviser) | |
Chris Fielding / James Sinclair-Ford | 020 7220 1666 |
Hybridan LLP (Nominated Broker) |
|
Claire Noyce | 020 3764 2341 |
Citigate Dewe Rogerson (Media enquiries) |
|
Shabnam Bashir/ Mark Swallow/ David Dible | 020 7638 9571 |
Notes for editors:
Sareum is a specialist drug development company delivering targeted small molecule therapeutics, to improve the treatment of cancer and autoimmune disease. The Company generates value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum's leading clinical-stage programme, SRA737, a novel Checkpoint kinase 1 (Chk1) inhibitor licensed to NASDAQ-listed Sierra Oncology, is in Phase 2 clinical trials targeting ovarian and other advanced cancers. The key role of Chk1 in cancer cell replication and DNA damage repair suggests that SRA737 may have broad application as a targeted therapy in combination with other oncology and immune-oncology drugs in genetically defined patients.
Sareum is also advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) /Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases (SDC-1801) and cancers (SDC-1802). TYK2 and JAK1 have roles in pro-inflammatory responses in autoimmune diseases (e.g. psoriasis, rheumatoid arthritis, inflammatory bowel diseases and lupus) and tumour cell proliferation in certain cancers (e.g. T-cell acute lymphoblastic leukaemia and some solid tumours). The Company is targeting first human clinical trials in each indication in 2020.
The Company also has an Aurora+FLT3 inhibitor targeting haematological cancers, which is at the preclinical development stage.
Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit www.sareum.co.uk
- Ends -